Technical Analysis for ARVN - Arvinas, Inc.

Grade Last Price % Change Price Change
grade B 15.99 1.14% 0.18
ARVN closed up 1.14 percent on Thursday, December 13, 2018, on 64 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical ARVN trend table...

Date Alert Name Type % Chg
Dec 12 20 DMA Resistance Bearish 1.14%
Dec 12 Fell Below 50 DMA Bearish 1.14%
Dec 12 MACD Bearish Centerline Cross Bearish 1.14%
Dec 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.14%
Dec 12 Outside Day Range Expansion 1.14%
Dec 11 Fell Below 20 DMA Bearish -4.93%
Dec 11 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.93%
Dec 11 NR7 Range Contraction -4.93%
Dec 11 Inside Day Range Contraction -4.93%
Dec 10 50 DMA Support Bullish -6.22%

Older signals for ARVN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
  • Earnings date: ???
Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Is ARVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 8 Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
Dec 4 Midday Gainers / Losers
Nov 20 Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference
Oct 23 Arvinas to Present at Two Protein Degradation Conferences
Oct 4 Arvinas Inc (ARVN) President and CEO John G Houston Bought $480,000 of Shares
Oct 3 The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares
Sep 27 Arvin's stock soars in its public debut, after upsized IPO priced at top of expected range
Sep 27 [$$] Biotech Arvinas Prices Upsized IPO at High End of Range
Sep 27 Arvinas prices upsized IPO at $16
Sep 27 Arvinas Announces Pricing of Initial Public Offering
See more ARVN news...
Indicators
Indicator Value
52 Week High 21.25
52 Week Low 13.7
Average Volume 68,433
200-Day Moving Average 0.0
50-Day Moving Average 16.349
20-Day Moving Average 16.7895
10-Day Moving Average 16.415
Average True Range 1.4158
ADX 18.14
+DI 8.4231
-DI 17.8485
Chandelier Exit (Long, 3 ATRs ) 14.2526
Chandelier Exit (Short, 3 ATRs ) 19.2374
Upper Bollinger Band 18.3691
Lower Bollinger Band 15.2099
Percent B (%b) 0.25
BandWidth 18.816522
MACD Line -0.1049
MACD Signal Line 0.056
MACD Histogram -0.1609
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.19
Resistance 3 (R3) 17.13 16.66 16.99
Resistance 2 (R2) 16.66 16.36 16.70 16.92
Resistance 1 (R1) 16.33 16.17 16.50 16.39 16.86
Pivot Point 15.86 15.86 15.95 15.90 15.86
Support 1 (S1) 15.53 15.56 15.70 15.59 15.12
Support 2 (S2) 15.06 15.37 15.10 15.06
Support 3 (S3) 14.73 15.06 14.99
Support 4 (S4) 14.79